VIVA Biotech Holdings has announced its unaudited condensed consolidated financial results for the six months ended June 30, 2025. The Group reported a revenue of RMB 831.9 million, a decline from RMB 981.8 million in the same period of 2024. Despite the decrease in revenue, VIVA Biotech achieved a net profit of RMB 148.6 million, up from RMB 144.2 million in the previous year. The company also reported an adjusted Non-IFRS net profit of RMB 183.5 million, an increase from RMB 168.2 million in 2024. The adjusted Non-IFRS net profit margin improved to 22.1% from 17.1% in the same period last year. Basic earnings per share attributable to ordinary equity holders of the parent increased to RMB 0.06 from RMB 0.05, while adjusted Non-IFRS basic earnings per share rose to RMB 0.07 from RMB 0.06. During the reporting period, the Group successfully invested in several high-quality assets, including portfolio companies such as Haya, Mediar, and Full-Life. Additionally, Hangzhou Viva Zongchen, a wholly-owned subsidiary, participated as a limited partner in the establishment and investment of an RMB-denominated fund, contributing RMB 25.0 million. This fund aims to support biopharmaceutical businesses and identify potential strategic partners to create synergies. Looking ahead, VIVA Biotech anticipates that its initial investments will gradually enter the harvesting phase, providing sustained cash returns and investment income as portfolio companies continue to develop and secure financing.